Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - olsalazine sodium, quantity: 250 mg - capsule - excipient ingredients: titanium dioxide; gelatin; magnesium stearate; caramel; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified water; industrial methylated spirit; ammonia - indications as at 19 december 2000: treatment of ulcerative colitis in patients intolerant of sulphasalazine.

United States - English - NLM (National Library of Medicine)

meda pharmaceuticals inc. - olsalazine sodium (unii: y7jew0xg7i) (olsalazine - unii:uls5i8j03o) - olsalazine sodium 250 mg - dipentum is indicated for the maintenance of remission of ulcerative colitis in adult patients who are intolerant of sulfasalazine. dipentum is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates or their metabolites, or to any of the excipients in dipentum.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - olsalazine sodium 250mg - capsule - 250 mg - active: olsalazine sodium 250mg excipient: gelatin magnesium stearate opacode black s-1-17822 opacode black s-1-17823 - maintenance of patients with ulcerative colitis in remission. treatment of acute ulcerative colitis of mild to moderate severity with or without the concomitant use of steroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - olsalazine sodium 500mg (plus overage 1.2%) - tablet - 500 mg - active: olsalazine sodium 500mg (plus overage 1.2%) excipient: colloidal silicon dioxide crospovidone magnesium stearate povidone

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - olsalazine sodium, quantity: 500 mg - tablet, uncoated - excipient ingredients: povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; ethanol - indications: treatment of ulcerative colitis in patients intolerant of sulphasalazine.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - olsalazine sodium -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - olsalazine sodium - oral capsule - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - olsalazine sodium - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - olsalazine sodium - oral capsule - 250mg

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - olsalazine sodium - capsule, hard - 250 milligram(s) - aminosalicylic acid and similar agents; olsalazine